Episode 16 - Neurofibromatosis Type 1-related Plexiform Neurofibromas: Key Advances from the 2025 Annual Oncology Conference (Chicago)
カートのアイテムが多すぎます
カートに追加できませんでした。
ウィッシュリストに追加できませんでした。
ほしい物リストの削除に失敗しました。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
Episode 16 - Neurofibromatosis Type 1-related Plexiform Neurofibromas: Key Advances from the 2025 Annual Oncology Conference (Chicago)
-
ナレーター：
-
著者：
このコンテンツについて
The introduction of kinase inhibitors has significantly impacted the treatment landscape of plexiform neurofibromas (PN) associated with neurofibromatosis type 1 (NF1). In this podcast activity from the 2025 Annual Oncology Meeting, noteworthy data in NF1-PN has been summarized and evaluated by Dr. Amy Armstrong. This activity is AMA/ABS/ANCC/ACPE accredited for one-year.
Launch Date: June 5, 2025
Release Date: June 5, 2025
Expiration Date: May 31, 2026
FACULTY
Amy Armstrong, MD
Assistant Professor of Pediatrics
Division of Hematology/Oncology
Neurofibromatosis (NF) Center
Washington University School of Medicine
St. Louis, Missouri
This podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided in this link prior to listening to this podcast.